Edwards Lifesciences

EW Health Care Market cap $49.3B as of Sep 14, 2026 16:00 ET S&P 500

Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 4, 2026

Revenue$1.74B +14% year over year

Gross profit$1.35B 77% margin

Operating profit$0.51B 29% margin

Net profit$0.24B 14% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.74	100%	+14%
Aortic valve replacement	1.26	72%	+11%
Surgical	0.28	16%
Transcatheter mitral	0.20	12%	+48%
Cost of revenue	−0.39	23%
Gross profit	1.35	77% margin
R&D	−0.28	16%	−2pp
SG&A	−0.56	32%	−1pp
Operating profit	0.51	29% margin	+3pp
Tax	−0.27
Net profit	0.24	14% margin	−8pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.65	100%	+17%
Aortic valve replacement	1.20	72%	+14%
Surgical	0.28	17%	+10%
Transcatheter mitral	0.18	11%	+52%
Cost of revenue	−0.36	22%
Gross profit	1.29	78% margin	−1pp
R&D	−0.26	16%	−2pp
SG&A	−0.52	32%	−1pp
Other	−0.02	1%	+0pp
Operating profit	0.48	29% margin	+1pp
Interest & other costs	−0.02
Tax	−0.08
Net profit	0.38	23% margin	−2pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.57	100%	+13%
Aortic valve replacement	1.16	74%	+12%
Surgical heart valve therapy	0.25	16%	+4%
Transcatheter mitral	0.16	10%	+48%
Cost of revenue	−0.34	22%
Gross profit	1.23	78% margin	−1pp
R&D	−0.27	17%	+0pp
SG&A	−0.60	39%	+0pp
Other	−0.21	13%	+0pp
Operating profit	0.15	10% margin	+0pp
Interest & other costs	−0.03
Tax	−0.03
Net profit	0.09	6% margin	−22pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.55	100%	+15%
Aortic valve replacement	1.15	74%	+12%
Surgical heart valve therapy	0.26	17%	+8%
Transcatheter mitral	0.15	9%	+59%
Cost of revenue	−0.35	22%
Gross profit	1.21	78% margin	−3pp
R&D	−0.28	18%	−1pp
SG&A	−0.51	33%	+2pp
Other	−0.11	7%
Operating profit	0.31	20% margin	−6pp
Other income, net	0.04
Tax	−0.06
Net profit	0.29	19% margin	−208pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.53	100%	+12%
Aortic valve replacement	1.13	74%	+9%
Surgical heart valve therapy	0.27	17%	+8%
Transcatheter mitral	0.14	9%	+62%
Cost of revenue	−0.34	22%
Gross profit	1.19	78% margin	−2pp
R&D	−0.28	18%	−2pp
SG&A	−0.50	33%	+0pp
Operating profit	0.41	27% margin	+0pp
Interest & other costs	−0.01
Tax	−0.06
Net profit	0.33	22% margin	−5pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY24 (period ends Sep 30, 2024).
Item	Value	Share of revenue	Year over year
Revenue	1.35	100%	+9%
Aortic valve replacement	1.02	75%	+6%
Surgical heart valve therapy	0.24	18%	+4%
Transcatheter mitral	0.09	7%	+74%
Cost of revenue	−0.26	19%
Gross profit	1.09	81% margin	+1pp
R&D	−0.25	19%	−1pp
SG&A	−0.42	31%	+0pp
Other	−0.07	5%	+0pp
Operating profit	0.35	26% margin	−4pp
Other income, net	2.76
Tax	−0.04
Net profit	3.07	227% margin	+196pp

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 4, 2026 Operating margin 29% Net profit $0.24B	Apr 1 – Jun 30, 2026	Aug 4, 2026	$1.74B	+14%	29%	$0.24B	14%
Q1 FY26 Jan 1 – Mar 31, 2026 reported May 6, 2026 Operating margin 29% Net profit $0.38B	Jan 1 – Mar 31, 2026	May 6, 2026	$1.65B	+17%	29%	$0.38B	23%
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 25, 2026 Operating margin 10% Net profit $0.09B	Oct 1 – Dec 31, 2025	Feb 25, 2026	$1.57B	+13%	10%	$0.09B	6%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Nov 5, 2025 Operating margin 20% Net profit $0.29B	Jul 1 – Sep 30, 2025	Nov 5, 2025	$1.55B	+15%	20%	$0.29B	19%
Q2 FY25 Apr 1 – Jun 30, 2025 reported Aug 6, 2025 Operating margin 27% Net profit $0.33B	Apr 1 – Jun 30, 2025	Aug 6, 2025	$1.53B	+12%	27%	$0.33B	22%
Q3 FY24 Jul 1 – Sep 30, 2024 reported Nov 6, 2024 Operating margin 26% Net profit $3.07B	Jul 1 – Sep 30, 2024	Nov 6, 2024	$1.35B	+9%	26%	$3.07B	227%